Prime Medicine, Inc. Retained Earnings
Prime Medicine, Inc. (PRME) had Retained Earnings of -$979.59 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$979.59M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$937.48M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$888.35M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$842.27M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$979.59M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$937.48M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$888.35M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$842.27M 10-Q · filed 2025-11-07 |
| 2025-06-30 | -$791.69M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$739.10M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$687.21M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$644.94M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$592.42M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$537.09M 10-Q · filed 2024-05-10 |
| 2023-12-31 | -$491.33M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$425.69M 10-Q · filed 2023-11-03 |
| 2023-06-30 | -$374.98M 10-Q · filed 2023-08-07 |
| 2023-03-31 | -$332.59M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$293.20M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$253.91M 10-Q · filed 2022-11-14 |
| 2021-12-31 | -$171.38M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |